1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Adderall XR faces first generic competition in US

 
• By Nancy Faigen

Teva Pharmaceutical Industries has launched its generic version of Shire's Adderall XR (amphetamine mixed salts) capsules in the US, in five strengths. Shire has been saying for some time that it expected an April 1st launch by Teva for the attention deficit hyperactivity disorder (ADHD) product. There is currently no generic competition in the US for the product.

Teva Pharmaceutical Industries has launched its generic version of Shire's Adderall XR (amphetamine mixed salts) capsules in the US, in five strengths. Shire has been saying for some time that it expected an April 1st launch by Teva for the attention deficit hyperactivity disorder (ADHD) product. There is currently no generic competition in the US for the product.

Shire is less reliant on Adderall XR now than it was in 2006 when the product accounted for 56% of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.